KKR Invests in Gentari’s Renewables Platform in India

KKR Invests in Gentari’s Renewables Platform in India

MUMBAI, India & KUALA LUMPUR, Malaysia–(BUSINESS WIRE)–
Clean energy solutions company Gentari and leading global investment firm KKR today announced that capital accounts advised by KKR have made a minority investment in Gentari Renewables India Pte Ltd, which holds Gentari’s renewables platform in India. ​​The investment will provide growth capital to support the platform’s continued expansion in the country.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118076160/en/

India remains a key market for Gentari, underpinned by increasing renewable energy demand, supportive market fundamentals and long-term opportunities. The investment marks an important milestone in the evolution of Gentari’s renewables platform in the country. Today, Gentari’s India platform has approximately 8 GW of operating, under-construction and contracted renewable energy capacity, with a robust development pipeline. The platform serves commercial and industrial customers, as well as government entities, through a diversified portfolio spanning solar, wind, hybrid and battery energy storage solutions, helping meet India’s growing clean energy needs. This reflects Gentari’s progress in scaling the business into one of its largest growth platforms. The strategic partnership with KKR brings together Gentari’s development, execution and operating capabilities with KKR’s long-term investment and deep infrastructure experience to support the platform’s next phase of growth.

Sushil Purohit, Group Chief Executive Officer, Gentari, commented, “This strategic partnership reflects confidence in the scale and maturity of the platform we have built in India as well as the strength of our growth trajectory. We are pleased to welcome KKR as an investor, given its long-term investment approach and deep experience supporting infrastructure and energy businesses globally. With KKR’s support, we are well-positioned to continue scaling the business as a self-sustaining renewable energy platform focused on long-term value creation.”

Hardik Shah, Partner, Asia Pacific Infrastructure, KKR, said, “India’s demand for reliable power is growing rapidly, creating a significant need for continued investment in the country’s energy infrastructure. We believe scaled platforms that can deliver increasingly sophisticated renewable energy solutions will have an important role to play in meeting that demand. Gentari has built strong capabilities across renewable generation, hybrid solutions and energy storage and we look forward to supporting the business in its next phase of growth.”

KKR has been investing in India’s infrastructure sector for more than a decade, with a focus on building and scaling platforms across sectors including renewable energy, power transmission, roads, logistics and transportation. In renewable energy, KKR has invested in Serentica Renewables and Hero Future Energies, building on KKR’s broader approach of supporting and scaling infrastructure platforms in India. Since 2011, KKR’s infrastructure platform has committed more than US$27 billion in energy transition and renewables infrastructure globally.

Following the investment, Gentari will continue to retain strategic oversight and operational control of the platform in India. This milestone reinforces Gentari’s long-term commitment to India and supports the next phase of expansion of its renewables platform in the country.

About Gentari

As part of the PETRONAS Group, Gentari is a clean energy solutions company operating across Renewable Energy, Hydrogen and Green Mobility. Through these businesses, Gentari supports customers in addressing evolving energy needs while balancing energy security, reliability, and affordability. With 9.1 GW of renewable energy capacity installed and under construction globally, Gentari has established a growing presence across key markets including Malaysia, India and Australia. Its renewable energy portfolio spans solar, onshore and offshore wind, and battery energy storage, while its hydrogen and green mobility businesses continue to expand. Gentari is also advancing cross-border energy initiatives, including renewable electricity interconnection opportunities in Southeast Asia. By combining expertise across its businesses, Gentari helps customers optimise energy systems, strengthen operational resilience, and create long-term value. Gentari aims to be Asia Pacific’s most valued clean energy solutions partner. For additional information, visit www.gentari.com.

About KKR

KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

Media Contacts

Gentari: Caroline Mak (Acendus) | +6019 579 9318 | [email protected]

KKR: Wei Jun Ong | +65 6922 5813 | [email protected]

KEYWORDS: New York United States India Southeast Asia North America Malaysia Asia Pacific

INDUSTRY KEYWORDS: Environment Utilities Sustainability Alternative Energy Green Technology Energy

MEDIA:

Logo
Logo
Logo
Logo

KRYS Investors Have Opportunity to Join Krystal Biotech, Inc. Fraud Investigation with SBS Law

KRYS Investors Have Opportunity to Join Krystal Biotech, Inc. Fraud Investigation with SBS Law

LOS ANGELES–(BUSINESS WIRE)–Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Krystal Biotech, Inc. (“Krystal” or “the Company”) (NASDAQ: KRYS) for violations of the securities laws.

INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Krystal reported its Q3 financial results on November 2, 2026. The Company revealed that data releases related to several of its products would be delayed to 2027 after previously stating that the data would be available in 2026. Based on this news, shares of Krystal fell by nearly 11%.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Schall, Brown & Schwartz LLP

Brian Schall, Esq.,

Andrew Brown, Esq.,

David Schwartz, Esq.,

www.schallfirm.com

Office: 310-301-3335

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo

Lost Money in BillionToOne, Inc. (NASDAQ: BLLN)? Gibbs Mura is Investigating Potential Securities Law Violations on Behalf of BLLN Investors

Lost Money in BillionToOne, Inc. (NASDAQ: BLLN)? Gibbs Mura is Investigating Potential Securities Law Violations on Behalf of BLLN Investors

OAKLAND, Calif.–(BUSINESS WIRE)–Shares of BillionToOne, Inc. (“BillionToOne”) fell over 6% on November 18, 2026, after Fuzzy Panda Research published a report alleging that the company is the subject of an undisclosed state Medicaid fraud investigation and has engaged in improper billing practices. Gibbs Mura is investigating a potential BillionToOne (NASDAQ: BLLN) Securities Class Action Lawsuit concerning whether BillionToOne has violated federal securities laws by providing false or misleading statements to investors.

YOU MAY BE ABLE TO RECOVER YOUR LOSSES. VISIT OUR BILLIONTOONE CLASS ACTION LAWSUIT INVESTIGATION WEBPAGE OR CALL US AT (888) 410-2925 TO LEARN MORE.

What is the BillionToOne Legal Investigation About?

BillionToOne is a California-based molecular diagnostics company that sells blood tests for prenatal screening and cancer care. On November 18, 2026, Fuzzy Panda Research published a report alleging that Tennessee Medicaid’s Office of Program Integrity referred the company to state investigators for suspected fraud in 2024, after receiving eleven tips. According to the Fuzzy Panda report, Tennessee investigators found that “a credible allegation of fraud has been established,” due to a pattern of inappropriate billing and violations of state and federal False Claims Acts. Fuzzy Panda claims BillionToOne has never disclosed this investigation to investors.

The report further alleges that BillionToOne is billing for carrier testing at a “suspiciously high rate,” and may be illegally submitting claims to Medicaid for medically unnecessary testing.

Following this news, shares of BillionToOne dropped over 6% on November 18, 2026, causing harm to investors.

What Should BillionToOne Investors Do?

If you purchased BillionToOne (NASDAQ: BLLN) stock and lost money, visit our BillionToOne securities class action investigation page or contact our firm’s securities fraud attorneys at(888) 410-2925 to get more information about how you may be able to recover your losses. All calls are free and confidential.

About Gibbs Mura

Gibbs Mura represents investors nationwide in securities litigation and has more than two decades of experience prosecuting fraud. The firm has recovered billions of dollars for its clients against some of the world’s largest corporations, and our attorneys have received numerous honors for their work, including “Best Lawyers in America,” “Top Plaintiff Lawyers in California,” “California Lawyer Attorney of the Year,” “Class Action Practice Group of the Year,” “Consumer Protection MVP,” and “Top Women Lawyers in California.”

This press release may constitute Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

PRESS CONTACT: DANI TISHKOFF
PHONE: 510.350.9723
EMAIL: [email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo

SBC Medical Group Reports Cybersecurity Incidents in Japan

SBC Medical Group Reports Cybersecurity Incidents in Japan

IRVINE, Calif.–(BUSINESS WIRE)–
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical Group” or the “Company”), a provider of comprehensive management services to medical corporations and their clinics, today reported the occurrence of recent cybersecurity incidents involving customer information associated with certain clinics in Japan, along with the status of its response.

Overview of the Incidents

On November 16, 2026, unauthorized access occurred to certain databases within a website system managed and operated by SBC Medical Group, Ltd., the Company’s, Japanese subsidiary, in connection with its management services in Japan. The Company confirmed that an unauthorized third party accessed and extracted customer information. The method of intrusion and full scope remain under investigation.

Based on current information, the information obtained and the number of affected customers are as follows:

Category

Types of information

Individuals

   

Period

Basic personal information (without reservation or treatment information)

Names, sex, telephone numbers, email addresses, passwords, addresses, dates of birth, patient card numbers, member IDs and survey responses (all or some of these items)*

1,624,000

   

2010–2023

Reservation requests through advertising, affiliate and campaign pages

Some or all of the foregoing categories of basic information, and reservation-request information

255,416

   

2007–2026

Inquiries submitted through website forms

Some or all basic information, and content entered in web inquiry forms

217,769

   

2004–2026

Treatment-monitor information

Some or all basic information, treatment descriptions, and stored image file names (not the images themselves)

4,513

   

2013–2026

Reviews submitted directly to the group

Some or all basic information, treatment names and review text

15,007

   

2015–2018

*Note: Information entered in the inquiry forms includes, in some cases, credit card information (14 individuals affected). The Company has confirmed that all of these credit cards were in a state in which additional payments could not be processed, such as having expired. The relevant period for entries in the inquiry forms is 2010–2018.

Customer passwords were also obtained. Employee account information, including names, IDs and passwords, was also obtained for employees of the Company’s group and the medical institutions it supports, involving approximately 20,000 records. For 459 employees, information provided at the time of employment, including bank account and pension-related information, withholding tax certificates and dependent exemption declarations, was also affected. Historical customer inquiries involving 14 individuals included credit card information. The categories and scope of affected information remain under investigation. As of the date of this release, the Company has not confirmed unauthorized acquisition of electronic medical records or information in the mySBC reservation site. Clinical care systems and direct treatment histories were outside the scope of the Company-managed database incident. The treatment-monitor information included image file names, not the images themselves.

Separately, on November 16, 2026, the Company was notified of unauthorized access to clinic administrator accounts on “Tribeau,” a third-party reservation service used by 56 clinics to which the Company provides management services. The platform operator identified the following accessed information :

Category

Types of information

Individuals

Reservation only

Kana name, telephone number, age, requested treatment, special menu and optional notes

12,641

Of the above, those who exchanged messages with the clinic

The above, plus message contents, date of birth and sex

3

Treatment received

Reservation information, treatment name and date, and treatment fee

6,804

The operator confirmed that the obtained information was not linked to case or review information, including photographs, on Tribeau. Email addresses, residential addresses, credit card information, passwords and electronic medical records were not included in that platform incident. The Company and the provider continue to investigate the access and its cause.

Response and Ongoing Investigation

After its security monitoring system detected anomalous activity on November 16, the Company took measures to isolate the affected server and block unauthorized access. It established an incident response team, preserved system logs, strengthened access restrictions and monitoring, and decided to commission a detailed investigation by external cybersecurity specialists.

Following notification from the Tribeau operator, all accounts of the clinics to which the Company provides management services on that platform had their passwords invalidated, and communications from the attacking sources were blocked. The Company continues to coordinate with the operator.

The Company reported the database incident to Japan’s Personal Information Protection Commission on November 16. The Company will take appropriate and firm action, including consulting with the police. As of the date of this release, the Company has not confirmed any fraudulent use or other secondary misuse of personal information resulting from the incidents.

Potential Business Impact

The Company is continuing to assess the potential impact of the incidents on its business, financial condition and results of operations.

The SBC core segment’s revenue comprises franchising, procurement, management services, rental services and other revenue streams. Fees for certain services are determined by factors including clinic size, services utilized and operational characteristics, while procurement and certain management services revenue components vary with clinic activity. Rental services revenue relates principally to medical equipment leased to medical corporations. The extent to which the incidents may affect these revenue streams remains uncertain. The Company also expects to incur costs related to customer notification, call center operations, forensic investigation, legal and advisory services, compensation and other response measures, a portion of which may be covered by cyber insurance maintained by its Japanese subsidiary, subject to policy terms and limits.

The relevant medical corporations have decided to suspend television and certain other advertising for a limited period following the incidents, and the Company expects that new patient inquiries at the affected clinics may decline during that period. Compensation payments may also arise.

The Company is currently unable to reasonably estimate the financial or other impacts of the incidents. The Company’s assessment will continue as its investigation progresses.

About SBC Medical Group Holdings Incorporated

SBC Medical is a Medical Services Organization providing management support across a wide range of healthcare fields, including advanced aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, hair loss treatment (AGA), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is expanding its global presence, particularly in the United States and Asia, through operations and medical tourism initiatives. The Company was listed on Nasdaq in September 2024 and was selected for inclusion in the Russell 3000® Index in June 2025.

For more information, visit https://sbc-holdings.com

For more insights and updates from SBC Medical, follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company’s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company’s control. These forward-looking statements reflect the Company’s current views with respect to, among other things, recent cybersecurity incidents; the Company’s plans and strategies for service expansion; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” “targets” or “hopes” or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, the scope and consequences of the cybersecurity incidents described in this release, including regulatory actions, litigation, remediation and response costs and effects on patient demand; changes in global, regional, or local economic, business, competitive, market and regulatory conditions; and those listed under the heading “Risk Factors” and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.

Investor Relations

SBC Medical Group Holdings Incorporated

[email protected]

Media Relations

SBC Medical Group Holdings Incorporated

[email protected]

KEYWORDS: United States Japan North America Asia Pacific California

INDUSTRY KEYWORDS: Data Management Practice Management Technology Other Health Health Security Medical Devices Apps/Applications Hospitals Surgery Internet

MEDIA:

Logo
Logo

CTVA Investors Have Opportunity to Join Corteva, Inc. Fraud Investigation with SBS Law

CTVA Investors Have Opportunity to Join Corteva, Inc. Fraud Investigation with SBS Law

LOS ANGELES–(BUSINESS WIRE)–Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corteva, Inc. (“Corteva” or “the Company”) (NYSE: CTVA) for violations of the securities laws.

INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Corteva released its Q3 2026 financial results on November 11, 2026. The Company reduced its full-year outlook, blaming the change on weak market conditions in Brazil. Based on this news, shares of Corteva fell by 24.3% on November 12, 2026.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo

SELLAS Life Sciences Announces Pricing of $150.0 Million Underwritten Public Offering

NEW YORK, Nov. 18, 2026 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the pricing of its previously announced underwritten public offering of 11,538,462 shares of its common stock at a public offering price of $13.00 per share. All of the shares in the offering will be sold by SELLAS, with gross proceeds to SELLAS expected to be $150.0 million before deducting underwriting discounts and commissions and offering expenses. In addition, SELLAS has also granted the underwriters a 30-day option to purchase up to 1,730,769 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on November 20, 2026, subject to the satisfaction of customary closing conditions.

J.P. Morgan and TD Cowen are acting as the lead book-running managers for the offering. Mizuho is also acting as a book-running manager for the offering. A.G.P./Alliance Global Partners and Maxim Group LLC are acting as lead managers for the offering.

The public offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-294504) that was previously filed with the Securities and Exchange Commission (the “SEC”) on March 20, 2026, and became automatically effective upon filing. The preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering has been filed with the SEC, and a final prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. The offering is being made only by means of a prospectus and related prospectus supplement, copies of which may be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected] and [email protected]; or TD Securities (USA) LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected].

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About SELLAS Life Sciences Group, Inc.

SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (tambiciclib), a small molecule CDK9 inhibitor, for the treatment of AML in patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases.

Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as “plan,” “expect,” “anticipate,” “may,” “might,” “will,” “should,” “project,” “believe,” “estimate,” “predict,” “potential,” “intend,” or “continue” and other words or terms of similar meaning. These statements include, without limitation, statements related to the expected closing of the public offering. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties, including the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the public offering, as well as risks and uncertainties inherent in SELLAS’ business, including those described in the company’s periodic filings with the SEC. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption “Risk Factors” in SELLAS’ Annual Report on Form 10-K filed on March 19, 2026 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date as of which the forward-looking statements were made.

Investor Contact

John Fraunces
Managing Director
LifeSci Advisors, LLC
[email protected]

Media Contact

Joan Bosisio
VP, Scientific & Medical Communications
Simpson Healthcare
[email protected]

Source: SELLAS Life Sciences Group, Inc.



CDNL Investors Have Opportunity to Join Cardinal Infrastructure Group Inc. Fraud Investigation with SBS Law

CDNL Investors Have Opportunity to Join Cardinal Infrastructure Group Inc. Fraud Investigation with SBS Law

LOS ANGELES–(BUSINESS WIRE)–Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cardinal Infrastructure Group Inc. (“Cardinal” or “the Company”) (NASDAQ: CDNL) for violations of the securities laws.

INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Cardinal reported its Q2 2026 financial results on August 11, 2026. The Company’s gross margin fell sharply year-over-year, with the Company explaining, “adjusted gross profit margin was impacted by increased subcontracted labor and equipment rental costs in certain developing markets, reflecting both customer demand and an intentional shift toward a more diversified, less residential-weighted project mix.” Based on this news, shares of Cardinal fell by 36%.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Schall, Brown & Schwartz LLP
Brian Schall, Esq.
Andrew Brown, Esq.
David Schwartz, Esq.
www.schallfirm.com
Office: 310-301-3335
[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo

Agencia Comercial Spirits Ltd Announces Execution of MEP Equipment Supply and Installation Contracts for Phase 1B of Indonesia Data Center

TAICHUNG, Taiwan, Nov. 18, 2026 (GLOBE NEWSWIRE) — Agencia Comercial Spirits Ltd (the “Company”) today announced that on November 13, 2026, its Indonesian operating subsidiary, PT AGCC AITECH INDONESIA (the “Indonesian Subsidiary”), entered into two definitive contracts with separate contractors for the mechanical, electrical and plumbing (“MEP”) works for Phase 1B of the Company’s planned AGCC-JKT01 data center in West Java, Indonesia (the “Data Center”): an equipment supply agreement for the procurement and supply of MEP equipment (the “Supply Contract”) and an installation works contract for the installation of the MEP equipment and systems (the “Installation Contract” and, together with the Supply Contract, the “Contracts”). The Contracts are in addition to the letters of award for the MEP equipment and installation works for Phase 1A of the Data Center previously announced by the Company on September 1, 2026.

The aggregate contract price under the Contracts is in a range between US$60 million and US$65 million, exclusive of Indonesian value-added tax. Each Contract is priced on a fixed lump-sum basis and is subject to adjustment only as provided in the relevant Contract, including for variations instructed by the Indonesian Subsidiary. The contract prices are denominated in U.S. dollars and are payable in Indonesian Rupiah at the Bank Indonesia middle rate on the relevant invoice date.

The Contracts provide for delivery of the equipment and completion of the installation works during 2027, in accordance with the milestones set out in the Contracts. Each Contract provides for liquidated damages for delay, subject to a cap, and for a defects notification period following taking-over of the installed works. The Indonesian Subsidiary may terminate either Contract for convenience on notice, subject to payment for work performed and other costs reasonably incurred by the relevant contractor.

The Contracts relate to the construction of the Data Center and do not themselves generate revenue. Completion of Phase 1B and commencement of operations at the Data Center remain subject to, among other things, performance by the contractors engaged by the Company and its subsidiaries (the “Group”), completion of related construction and power supply works, availability of funding and applicable regulatory approvals. The Contracts do not by themselves guarantee successful completion of Phase 1B or of the Data Center, or operational capacity, customer utilization, revenue, profitability or positive cash flow.

About Agencia Comercial Spirits Ltd

Agencia Comercial Spirits Ltd is a Nasdaq-listed company with two principal business focuses: (i) its established premium whisky operations; and (ii) the development of AI computing infrastructure and cloud-based computing services. These two lines of business represent the Company’s primary operational pillars, with the Company dedicating substantial resources to the development and scaling of its AI computing infrastructure business. The Company’s whisky operations include procurement and distribution of bottled whisky, procurement and distribution of raw cask whisky, and cask-to-bottle and distribution services, including brand-authorized bottling, packaging and sales, in Taiwan and select international markets.

Since early 2026, the Company has launched and been developing its AI Computing Infrastructure Initiative through subsidiaries in Singapore, Indonesia and other jurisdictions. This initiative represents a principal business focus, backed by substantive contractual arrangements for commercial AI computing cloud services and the development of supporting data center, power, network and technical infrastructure. The Company’s historical operating revenue has been derived from its whisky operations, and the AI computing business remains in development and deployment and is subject to significant business, financing, construction, technology, regulatory, customer demand and execution risks.
  
Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. federal securities laws. These include statements concerning the manufacture, delivery, installation, testing and completion of the MEP equipment and works; the timing of Phase 1B and of the Data Center; future payments and expenditure under the Contracts; and the Company’s intended development and operation of its AI computing infrastructure business. Words such as “may,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “could” and similar expressions may identify forward-looking statements, although not all such statements contain these words.

These statements are based on management’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Manufacturing, shipping, customs clearance, installation and testing may be delayed; contractors and their suppliers may fail to perform; and liquidated damages and other contractual remedies may be insufficient to compensate the Group for delay or defective performance. Variations, related construction and power supply works and other project costs may increase total expenditure, and funding may not be available when required or on acceptable terms. Changes in exchange rates, taxes, import and customs requirements, permits and other regulatory requirements may delay the project or increase its cost. Additional risks include insufficient customer demand, competition, technological change and operational interruptions. The Group may incur substantial payment obligations before or without corresponding customer receipts. These matters could materially adversely affect the Company’s business, financial condition and results of operations.

Further risks and uncertainties are described in the Company’s reports and other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date of this press release, and readers should not place undue reliance on them. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.

Investor and Media Contact

Agencia Comercial Spirits Ltd
No. 23-1, Shenzun Rd., Shengang Dist.
Taichung City 429014, Taiwan (R.O.C.)
Phone: +886-4-2254-0373
Email: [email protected]



BlackRock Declares Quarterly Dividend of $5.73 on Common Stock

BlackRock Declares Quarterly Dividend of $5.73 on Common Stock

NEW YORK–(BUSINESS WIRE)–
BlackRock, Inc. (NYSE:BLK) today announced that its Board of Directors has declared a quarterly cash dividend of $5.73 per share of common stock, payable December 22, 2026 to shareholders of record at the close of business on December 8, 2026.

About BlackRock

BlackRock’s purpose is to help more and more people experience financial well-being. As a fiduciary to investors and a leading provider of financial technology, we help millions of people build savings that serve them throughout their lives by making investing easier and more affordable. For additional information on BlackRock, please visit www.blackrock.com/corporate.

Investor Relations

Caroline Rodda

212-810-3442

[email protected]

Media Relations

Patrick Scanlan

212-810-3622

[email protected]

 

 

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Asset Management Professional Services Finance

MEDIA:

Logo
Logo

Walker & Dunlop Arranges $270 Million Refinancing for Nasser Freres’ The Greyson in Jersey City

Walker & Dunlop Arranges $270 Million Refinancing for Nasser Freres’ The Greyson in Jersey City

BETHESDA, Md.–(BUSINESS WIRE)–Walker & Dunlop, Inc. announced today that it has arranged $270,000,000 in refinancing for The Greyson, a 28-story, 622-unit, Class A mixed-use residential tower developed by Nasser Freres in the heart of Jersey City’s Journal Square neighborhood. The financing marks a significant milestone for the development, supporting its transition from construction to stabilized operations and positioning the property for long-term success.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118022862/en/

The Greyson. Photo credits: Nasser Freres

The Greyson. Photo credits: Nasser Freres

Walker & Dunlop Capital Markets Institutional Advisory served as exclusive advisor to Nasser Freres, arranging a floating-rate, interest-only bridge loan from affiliates of Apollo. The transaction was arranged by Keith Kurland, Aaron Appel, Adam Schwartz, Jonathan Schwartz, Jordan Casella, Christopher de Raet, and Jack Krentzman.

“Journal Square has undergone a remarkable transformation, and The Greyson exemplifies the caliber of development attracting investment to the neighborhood,” said Kurland, senior managing director of Capital Markets and co-head of Institutional Advisory at Walker & Dunlop. “With its exceptional location, extensive amenities, and proximity to Manhattan, the property is well-positioned to capitalize on the area’s continued growth. We’re pleased to have worked with Nasser Freres and Apollo to execute this transaction.”

Located at 25 Cottage Street, The Greyson encompasses 424,328 rentable square feet, including 389,328 square feet of residential and 35,000 square feet of commercial space. The property features a collection of studio, one-, two-, and three-bedroom residences with unobstructed views of the Jersey City skyline. Designed to deliver an elevated residential experience, The Greyson offers an extensive suite of amenities, including an art gallery, children’s playroom, screening room, gaming lounge, virtual reality and sports room, coffee bar, fitness center, speakeasy, and private event space. Ground-floor retail space leased to a wine bar further enhances the property’s appeal while contributing to Journal Square’s growing dining and entertainment scene.

“From the outset, our vision for The Greyson was to create something truly distinctive, a property that would help shape the next chapter of residential living in Journal Square while contributing meaningfully to the neighborhood’s continued transformation,” said Michael Sokoloff, partner at Nasser Freres. “We’ve been intentional about every aspect of this development, from its architecture and design to the amenities and experiences we’re bringing to residents. We’re incredibly proud of what we’ve built and believe The Greyson will set a new standard for the neighborhood for years to come. This refinancing marks an exciting next chapter as we shift our focus to the property’s long-term success and we appreciate Walker & Dunlop’s advisory.”

Situated along the newly opened Homestead commercial corridor, the property is less than a five-minute walk from the Journal Square Transportation Center, offering direct PATH access to Lower and Midtown Manhattan in approximately 10 and 20 minutes, respectively. Journal Square has emerged as one of the New York metropolitan area’s fastest-growing rental submarkets, driven by demand for transit-oriented housing and rental rates that remain comparatively affordable to those along the Jersey City Waterfront and in Manhattan.

In the first half of 2026, Walker & Dunlop’s Capital Markets team sourced over $13.9 billion from non-Agency capital providers, including nearly $9.6 billion for multifamily properties. This vast experience has made them a top advisor on all asset classes for many of the industry’s top developers, owners, and operators. To learn more about Walker & Dunlop’s broad financing options, visit our website.

About Walker & Dunlop

Walker & Dunlop (NYSE: WD) is one of the largest commercial real estate finance and advisory services firms in the United States and internationally. Our ideas and capital create communities where people live, work, shop, and play. Our innovative people, breadth of our brand, and our technological capabilities make us one of the most insightful and client-focused firms in the commercial real estate industry.

Media:

Nina H. von Waldegg

Public Relations

Phone 301.564.3291

[email protected]

Phone 301.215.5500

7272 Wisconsin Avenue, Suite 1300

Bethesda, Maryland 20814

KEYWORDS: United States North America Maryland

INDUSTRY KEYWORDS: Commercial Building & Real Estate Construction & Property Finance Public Relations/Investor Relations Communications Professional Services Other Construction & Property Residential Building & Real Estate

MEDIA:

Photo
Photo
The Greyson. Photo credits: Nasser Freres
Logo
Logo